Catalyst Drug Patent Portfolio
Catalyst owns 3 orange book drugs protected by 15 US patents Given below is the list of Catalyst's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11382922 | Aqueous oral pharmaceutical suspension compositions | 16 Jul, 2040 | Active |
| US11471471 | Aqueous oral pharmaceutical suspension compositions | 17 Mar, 2040 | Active |
| US12201639 | Aqueous oral pharmaceutical suspension compositions | 17 Mar, 2040 | Active |
| US10626088 | Determining degradation of 3,4-diaminopyridine | 25 Feb, 2037 | Active |
| US10793893 | Methods of administering 3,4-diaminopyridine | 26 May, 2034 | Active |
| US11690853 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | 07 Mar, 2033 | Active |
| US11060128 | Methods of administering 3,4-diaminopyridine | 29 Jun, 2032 | Active |
| US11268128 | Methods of administering 3,4-diaminopyridine | 29 Jun, 2032 | Active |
| US11274331 | Methods of administering 3,4-diaminopyridine | 29 Jun, 2032 | Active |
| US11274332 | Methods of administering 3,4-diaminopyridine | 29 Jun, 2032 | Active |
| US10857161 | Non-hormonal steroid modulators of NF-kB for treatment of disease | 28 May, 2029 | Active |
| US11833159 | Non-hormonal steroid modulators of NF-kB for treatment of disease | 28 May, 2029 | Active |
| US8334279 | Non-hormonal steroid modulators of NF-κB for treatment of disease | 28 May, 2029 | Active |
| US8772497 | Method for producing 1, 2-dihydropyridine-2-one compound | 01 Jul, 2026 | Active |
| US6949571 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | 23 May, 2025 | Expired |
Latest Legal Activities on Catalyst's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Catalyst.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Sep, 2025 | US11268128 |
| transaction for FDA Determination of Regulatory Review Period | 20 Jun, 2025 | US11690853 |
| transaction for FDA Determination of Regulatory Review Period | 20 Jun, 2025 | US10857161 |
| transaction for FDA Determination of Regulatory Review Period | 02 May, 2025 | US10857161 |
| transaction for FDA Determination of Regulatory Review Period | 02 May, 2025 | US11690853 |
| Recordation of Patent Grant Mailed | 21 Jan, 2025 | US12201639 |
| Patent Issue Date Used in PTA Calculation | 21 Jan, 2025 | US12201639 |
| Recordation of Patent eGrant | 21 Jan, 2025 | US12201639 |
| Mail Patent eGrant Notification | 21 Jan, 2025 | US12201639 |
| Email Notification | 21 Jan, 2025 | US12201639 |
| Patent eGrant Notification | 21 Jan, 2025 | US12201639 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Jan, 2025 | US11060128 |
| Email Notification | 01 Jan, 2025 | US12201639 |
| Issue Notification Mailed | 01 Jan, 2025 | US12201639 |
| Dispatch to FDC | 26 Dec, 2024 | US12201639 |
Catalyst's Family Patents
Catalyst Drug List
Given below is the complete list of Catalyst's drugs and the patents protecting them.
1. Agamree
Agamree is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11382922 | Aqueous oral pharmaceutical suspension compositions |
16 Jul, 2040
(14 years from now)
| Active |
| US11471471 | Aqueous oral pharmaceutical suspension compositions |
17 Mar, 2040
(14 years from now)
| Active |
| US12201639 | Aqueous oral pharmaceutical suspension compositions |
17 Mar, 2040
(14 years from now)
| Active |
| US11690853 | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
07 Mar, 2033
(6 years from now)
| Active |
| US10857161 | Non-hormonal steroid modulators of NF-kB for treatment of disease |
28 May, 2029
(3 years from now)
| Active |
| US11833159 | Non-hormonal steroid modulators of NF-kB for treatment of disease |
28 May, 2029
(3 years from now)
| Active |
| US8334279 | Non-hormonal steroid modulators of NF-κB for treatment of disease |
28 May, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Agamree's drug page
2. Firdapse
Firdapse is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10626088 | Determining degradation of 3,4-diaminopyridine |
25 Feb, 2037
(10 years from now)
| Active |
| US10793893 | Methods of administering 3,4-diaminopyridine |
26 May, 2034
(8 years from now)
| Active |
| US11060128 | Methods of administering 3,4-diaminopyridine |
29 Jun, 2032
(6 years from now)
| Active |
| US11268128 | Methods of administering 3,4-diaminopyridine |
29 Jun, 2032
(6 years from now)
| Active |
| US11274331 | Methods of administering 3,4-diaminopyridine |
29 Jun, 2032
(6 years from now)
| Active |
| US11274332 | Methods of administering 3,4-diaminopyridine |
29 Jun, 2032
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Firdapse's drug page
3. Fycompa
Fycompa is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8772497 | Method for producing 1, 2-dihydropyridine-2-one compound |
01 Jul, 2026
(3 months from now)
| Active |
| US6949571 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
23 May, 2025
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fycompa's drug page